Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.

New humanized mouse model provides insight into immunotherapy resistance

Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas

Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival

Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.